DrugCLIP: Contrastive Drug-Disease Interaction For Drug Repurposing

• URL: http://arxiv.org/abs/2407.02265v1
• Date: Tue, 2 Jul 2024 13:41:59 GMT
• Title: DrugCLIP: Contrastive Drug-Disease Interaction For Drug Repurposing
• Authors: Yingzhou Lu, Yaojun Hu, Chenhao Li,
• Abstract summary: DrugCLIP is a contrastive learning method to learn drug and disease's interaction without negative labels. We have curated a drug repurposing dataset based on real-world clinical trial records.
• Score: 4.969453745531116
• License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
• Abstract: Bringing a novel drug from the original idea to market typically requires more than ten years and billions of dollars. To alleviate the heavy burden, a natural idea is to reuse the approved drug to treat new diseases. The process is also known as drug repurposing or drug repositioning. Machine learning methods exhibited huge potential in automating drug repurposing. However, it still encounter some challenges, such as lack of labels and multimodal feature representation. To address these issues, we design DrugCLIP, a cutting-edge contrastive learning method, to learn drug and disease's interaction without negative labels. Additionally, we have curated a drug repurposing dataset based on real-world clinical trial records. Thorough empirical studies are conducted to validate the effectiveness of the proposed DrugCLIP method.

Related papers

• Modeling Path Importance for Effective Alzheimer's Disease Drug Repurposing [8.153491945775734]
  We propose MPI (Modeling Path Importance), a novel network-based method for AD drug repurposing. MPI prioritizes important paths via learned node embeddings, which can effectively capture a network's rich structural information. We observe that among the top-50 ranked drugs, MPI prioritizes 20.0% more drugs with anti-AD evidence compared to the baseline.
  arXiv  Detail & Related papers  (2023-10-23T17:24:11Z)
• Zero-shot Learning of Drug Response Prediction for Preclinical Drug Screening [38.94493676651818]
  We propose a zero-shot learning solution for the. task in preclinical drug screening. Specifically, we propose a Multi-branch Multi-Source Domain Adaptation Test Enhancement Plug-in, called MSDA.
  arXiv  Detail & Related papers  (2023-10-05T05:55:41Z)
• NeuroCADR: Drug Repurposing to Reveal Novel Anti-Epileptic Drug Candidates Through an Integrated Computational Approach [0.0]
  Drug repurposing is an emerging approach for drug discovery involving the reassignment of existing drugs for novel purposes. A proposed algorithm is NeuroCADR, a novel system for drug repurposing via a multi-pronged approach consisting of k-nearest neighbor algorithms (KNN), random forest classification, and decision trees. Data was sourced from several databases consisting of interactions between diseases, symptoms, genes, and affiliated drug molecules, which were then compiled into datasets expressed in binary. NeuroCADR identified novel drug candidates for epilepsy that can be further approved through clinical trials.
  arXiv  Detail & Related papers  (2023-09-04T03:21:43Z)
• Drug Synergistic Combinations Predictions via Large-Scale Pre-Training and Graph Structure Learning [82.93806087715507]
  Drug combination therapy is a well-established strategy for disease treatment with better effectiveness and less safety degradation. Deep learning models have emerged as an efficient way to discover synergistic combinations. Our framework achieves state-of-the-art results in comparison with other deep learning-based methods.
  arXiv  Detail & Related papers  (2023-01-14T15:07:43Z)
• Knowledge-Driven New Drug Recommendation [88.35607943144261]
  We develop a drug-dependent multi-phenotype few-shot learner to bridge the gap between existing and new drugs. EDGE eliminates the false-negative supervision signal using an external drug-disease knowledge base. Results show that EDGE achieves 7.3% improvement on the ROC-AUC score over the best baseline.
  arXiv  Detail & Related papers  (2022-10-11T16:07:52Z)
• Deep learning for drug repurposing: methods, databases, and applications [54.08583498324774]
  Repurposing existing drugs for new therapies is an attractive solution that accelerates drug development at reduced experimental costs. In this review, we introduce guidelines on how to utilize deep learning methodologies and tools for drug repurposing.
  arXiv  Detail & Related papers  (2022-02-08T09:42:08Z)
• SafeDrug: Dual Molecular Graph Encoders for Safe Drug Recommendations [59.590084937600764]
  We propose a DDI-controllable drug recommendation model named SafeDrug to leverage drugs' molecule structures and model DDIs explicitly. On a benchmark dataset, our SafeDrug is relatively shown to reduce DDI by 19.43% and improves 2.88% on Jaccard similarity between recommended and actually prescribed drug combinations over previous approaches.
  arXiv  Detail & Related papers  (2021-05-05T00:20:48Z)
• MolDesigner: Interactive Design of Efficacious Drugs with Deep Learning [61.74958429818077]
  MolDesigner is a human-in-the-loop web user-interface (UI) for drug developers. A developer can draw a drug molecule in the interface. In the backend, more than 17 state-of-the-art DL models generate predictions on important indices that are crucial for a drug's efficacy.
  arXiv  Detail & Related papers  (2020-10-05T21:25:25Z)
• Two Step Joint Model for Drug Drug Interaction Extraction [82.49278654043577]
  Drug-Drug Interaction (DDI) Extraction from Drug Labels challenge of Text Analysis Conference (TAC) 2018. We propose a two step joint model to detect DDI and it's related mentions jointly. A sequence tagging system (CNN-GRU encoder-decoder) finds precipitants first and search its fine-grained Trigger and determine the DDI for each precipitant in the second step.
  arXiv  Detail & Related papers  (2020-08-28T15:30:08Z)
• When deep learning meets causal inference: a computational framework for drug repurposing from real-world data [12.68717103979673]
  Existing methods for drug repurposing may exist translational issues when applied to human beings. We present an efficient and easily-customized framework for generating and testing multiple candidates for drug repurposing. We demonstrate our framework in a case study of coronary artery disease (CAD) by evaluating the effect of 55 repurposing drug candidates on various disease outcomes.
  arXiv  Detail & Related papers  (2020-07-16T21:30:56Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.